Atavistik Bio Partners with Cure HHT Clinical Trial Network and Activates First Clinical Site

Cure HHT is proud to partner with Atavistik Bio as it advances ATV-1601, an investigational oral therapy for people with moderate to severe HHT. With Atavistik now joining the Cure HHT Clinical Trial Network, we will serve as the patient advocacy partner for the Harmony-HHT Phase 1/2 study—helping provide education, build awareness, and engage the global HHT community as the trial progresses. The activation of the study’s first clinical site at the Massachusetts General Hospital HHT Center of Excellence marks an important step forward, and we are incredibly pleased to share this momentum with our community. This partnership reflects exactly why the Clinical Trial Network was created: to connect promising research with experienced HHT clinicians, trial-ready Centers of Excellence, and the patients and families who make progress possible. Together, Cure HHT and Atavistik will work to expand global interest in the Harmony-HHT study and help eligible individuals learn more about opportunities to participate.

“We are thrilled to welcome Atavistik Bio to the Cure HHT Clinical Trial Network and to support the advancement of the Harmony-HHT study,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Our community has waited far too long for therapies developed specifically for HHT, and every new clinical program brings renewed reason for hope. By connecting Atavistik with our global network of patients, clinicians, and Centers of Excellence, we can help ensure the HHT community is informed, engaged, and meaningfully represented as this important work moves forward.”